Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst
There were two additions to the index unveiled on Friday— Marvell Technology and Flex (formerly Flextronics)—and that raises the question which companies could be next to gain admission into the
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after agreeing to a collaboration with Inceptive Nucleics valued at up to US$2b, centered on using generative AI models to accelerate RNAi drug
The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. June E-mi
Large-cap biotech stocks may be entering a very different phase from the one investors have dealt with during the past several years. After a lengthy period dominated by clinical uncertainty, cash bur
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
View interactive chart, options flow, and AI analysis for ALNY on Zorveq Finance.
Open ALNY Chart & Analysis →